These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 9456275

  • 1. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
    Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S.
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
    [Abstract] [Full Text] [Related]

  • 2. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.
    Osamah H, Mira R, Sorina S, Shlomo K, Michael A.
    Br J Clin Pharmacol; 1997 Jul; 44(1):77-83. PubMed ID: 9241100
    [Abstract] [Full Text] [Related]

  • 3. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
    Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, Imaizumi T.
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1471-7. PubMed ID: 17379842
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H, Fager G.
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [Abstract] [Full Text] [Related]

  • 5. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
    Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M.
    Atherosclerosis; 1997 Jan 03; 128(1):11-8. PubMed ID: 9051193
    [Abstract] [Full Text] [Related]

  • 6. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages.
    Tanaka K, Yasuhara M, Suzumura K, Narita H, Suzuki T.
    Jpn J Pharmacol; 2001 Jul 03; 86(3):289-96. PubMed ID: 11488428
    [Abstract] [Full Text] [Related]

  • 7. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
    Yasuhara M, Suzumura K, Tanaka K, Takahashi M, Aoki S, Odawara A, Narita H, Suzuki T.
    Biol Pharm Bull; 2000 May 03; 23(5):570-4. PubMed ID: 10823666
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I, Spinler SA, Johnson NE.
    Ann Pharmacother; 1995 May 03; 29(7-8):743-59. PubMed ID: 8520093
    [Abstract] [Full Text] [Related]

  • 10. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages.
    Bernini F, Scurati N, Bonfadini G, Fumagalli R.
    Arterioscler Thromb Vasc Biol; 1995 Sep 03; 15(9):1352-8. PubMed ID: 7670949
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
    Suzumura K, Odawara A, Yasuhara M, Tanaka K, Narita H, Suzuki T.
    Biol Pharm Bull; 1999 Sep 03; 22(9):971-4. PubMed ID: 10513623
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
    Suzumura K, Tanaka K, Yasuhara M, Narita H.
    Biol Pharm Bull; 2000 Jul 03; 23(7):873-8. PubMed ID: 10919369
    [Abstract] [Full Text] [Related]

  • 14. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

  • 15. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
    Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M.
    Am J Kidney Dis; 2003 May 13; 41(5):1088-96. PubMed ID: 12722044
    [Abstract] [Full Text] [Related]

  • 16. The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
    Lin TH, Huang CH, Voon WC, Yen HW, Lai HM, Liang HY, Lu YH, Lee KT, Lee CS, Lai WT, Sheu SH.
    Kaohsiung J Med Sci; 2000 Dec 13; 16(12):600-6. PubMed ID: 11392099
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
    Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis A.
    Am J Cardiol; 1995 Jul 13; 76(2):62A-64A. PubMed ID: 7604801
    [Abstract] [Full Text] [Related]

  • 19. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H, Hartmann A, Stenstrøm J, Dahl KJ, Borge M, Pfister P.
    Am J Cardiol; 1995 Jul 13; 76(2):102A-106A. PubMed ID: 7604781
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.